FDA
-
-
-
-
-
-
-
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
-
-
-
-
-
-
-
Xencor (XNCR), MorphoSys (MOR) and Incyte (INCY) Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
-
-
-
-
-
-
-
Aimmune Therapeutics (AIMT) Reports Licensing of Exclusive Worldwide Rights to Xencor (XNCR) XmAb7195 for Development of Next-Generation Food Allergy Treatments
-
-
-
-
-
-
-
Xencor (XNCR) Announces Partial Clinical Hold on Phase 1 Study of XmAb14045
-
-
-
-
-
-
-
Xencor Reports Fourth Quarter and Full Year 2017 Financial Results
-
-
-
-
-
-
-
Xencor (XNCR) Appoints Kevin Gorman to Board of Directors
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

